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1254mutations identified in 277 patients revealed that those hot spots
account for 68.5% of patients (37 of 54) with mosaic mutations.
Glu569 is affected in 22% of the patients (12 of 54) with mosaic
mutations and in 0.4% of patients (1 of 223) with germline
mutations. Only 8 of 90 mutations were found in mosaic and
germinal states. All of the germline mutations were associated
with a severe phenotype. These data suggest that mutations
found only in mosaic state could be incompatible with life if
present in germinal state. None of the 5 most frequent germline
mutations was identified in mosaic state. Mutations found only
in germinal state could, therefore, be asymptomatic in mosaic
state.
Conclusions: The phenotypic spectrum of NLRP3-AIDs appears
to be related to the germinal/mosaic status and localization of
the underlying mutations. (J Allergy Clin Immunol
2020;145:1254-61.)
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Autoinflammatory diseases (AIDs) are associated with recur-
rent episodes of fever, sterile inflammation of joints and serosal
membranes, skin rashes, lymphadenopathy, musculoskeletal
symptoms, and biological inflammation. NLRP3-AIDs are a
group of monogenic AIDs related to germline or somatic
NLRP3 mutations leading to NLRP3-inflammasome activation.1
The NLRP3 inflammasome is an intracellular multiprotein
signaling complex that assembles around NLRP3, the adaptor
protein apoptosis-associated speck-like protein containing a
CARD (ASC), and the procaspase 1 leading to autoproteolytic
activation of caspase-1 and secretion of proinflammatory cyto-
kines (mainly IL1b).2
The NLRP3 protein comprises an N-terminal pyrin domain, a
central nucleotide-binding and oligomerization domain (NACHT,
which stands for NAIP, CIITA, HET-E, and TP1), and C-terminal
leucine-rich repeats (LRRs). NACHT is an ATPase domain
including a nucleotide binding domain (NBD) that contains
Walker A (ATP binding) andWalker B (Mg21 binding) catalytic
motifs, the helical domain 1 (HD1), a winged HD, and the helical
domain (HD2). Through the NBD, HD2, and LRR regions,
NLRP3 interacts with the Ser/Thr kinase NEK7 that mediates
NLRP3-inflammasome activation.3
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LOUVRIER ET AL 1255Abbreviations usedAID: Autoinflammatory diseaseASC: Apoptosis-associated speck-like protein containing
a CARDCAPS: Cryopyrin-associated periodic syndromeCINCA: Chronic infantile neurological, cutaneous, and
articular syndromeCpG: Cytosine-phosphate-guanineEV: Empty vectorFCAS: Familial cold autoinflammatory syndromeGFP: Green fluorescent proteinHD1 (2): Helical domain 1 (2)LRR: Leucine-rich repeatMAP: Mutated allele percentageMWS: Muckle-Wells syndromeNACHT domain: Nucleotide-binding and oligomerization domain
(standing for NAIP, CIITA, HET-E, and TP1)NBD: Nucleotide binding domainNGS: Next-generation sequencingNLRP3-AID: NLRP3-associated autoinflammatory diseaseOMIM: Online Mendelian Inheritance in ManWT: Wild-typeNLRP3-AIDs, previously known as cryopyrin-associated peri-
odic syndromes (CAPSs), include 3 overlapping entities with
increasing severity: (1) the familial cold autoinflammatory syn-
drome (FCAS, Online Mendelian Inheritance in Man [OMIM]
120100) characterized by cold-induced inflammatory episodes
of fever, arthralgia, and urticaria; (2) the Muckle-Wells syndrome
(MWS, OMIM 191900) associating recurrent attacks of fever, ur-
ticaria, and arthritis with subsequent sensorineural hearing loss;
and (3) the chronic infantile neurological, cutaneous, and articular
syndrome (CINCA, OMIM 607115) characterized by central ner-
vous system involvement, continuous urticarial rash, and defor-
mative joint arthritis.
Primarily related to germline heterozygous NLRP3 mutations,
NLRP3-AIDs were described in familial forms of AIDs trans-
mitted as autosomal dominant traits,4 as well as in sporadic cases
due to de novo NLRP3mutations.5,6 The identification of somatic
mosaic NLRP3mutations has further broadened the clinical spec-
trum of NLRP3-AIDs7,8 with the reports of late onset diseases9-11
and paucisymptomatic forms.12 The advances in next-generation
sequencing (NGS) technologies have led to the identification of
an increasing number of NLRP3 sequence variations in AID pa-
tients, raising the question of the pathogenicity of the identified
sequence variations.
In this study, in an attempt to identify possible germline- and
mosaic-specific features of NLRP3 mutations, we reassessed all
previously reported NLRP3 variations identified in NLRP3-AID
patients. To evaluate the functional impact of the mutations, we
studied their molecular characteristics such as their location on
the 3-dimensional structure of the NLRP3 protein and the amino
acid change, as well as their associated phenotypic severity. In
this study, we also took into account 3 unrelated NLRP3-AID pa-
tients with mosaic variations involving the same amino acid. One
of those patients also carried a novel germline variation. We as-
sessed the pathogenicity of the identified variants through intrafa-
milial segregation for the germline one and by performing
inflammasome-activation studies.METHODS
Patients
Clinical features were collected through a standardized form. The study
conforms to the Helsinki declaration regarding ethical principles for medical
research. Written informed consent was obtained from each patient or their
parents.Study of the NLRP3 gene
Genomic DNAwas extracted from peripheral blood leukocytes of patients
and parents from proband III using standard procedures. PBMCswere isolated
from peripheral blood using Lymphocyte Separating Medium, Pancoll human
(PAN-Biotech, Aidenbach, Germany). PBMCs were separated by positive
selection using immunomagnetic microbeads (MACS; Miltenyi Biotec,
Bergisch Gladbach, Germany), anti-CD14 (monocytes) followed by anti-
CD15 (neutrophils), anti-CD19 (B cells), and anti-CD3 (T cells). DNA was
then extracted frommonocytes, neutrophils, B cells, T cells, urine, and buccal
cells using proteinase K digestion followed by a phenol-chloroform extraction
protocol.
Sanger sequencing. NLRP3 exon 3 and its intronic junctions were
amplified by PCR and sequenced using the BigDye Terminator sequencing kit
(Applied Biosystems, Foster City, Calif) on an ABI 3130XL automated capil-
lary DNA sequencer (Applied Biosystems). Sequences were analyzed against
the reference sequence (NM_004895).
Next generation sequencing. Next-generation sequencing
(NGS) was performed using a custom sequence capture (Nimblegen SeqCap
EZ Choice system; Roche Sequencing, Pleasanton, Calif) of the exons and
the flanking intronic sequences of the main AID-causing genes: ADA2,
CARD14, IL1RN, IL36RN, LACC2, LPIN2, MEFV, MVK, NLRC4,
NLRP12, NLRP3, NOD2, PLCG2, PSMB8, PSTPIP1, RBCK1, TMEM173,
TNFAIP3, TNFRSF11A, and TNFRSF1A. Sequencing was performed on
MiSeq or Nextseq500 (Illumina, San Diego, Calif) platforms according to
the manufacturer’s instructions. The conventional bioinformatics pipeline,
previously described,13 was used to study germline mutations. For the
mosaic-dedicated bioinformatics pipeline, sequence reads in fastq format
were aligned to the reference human genome (hg19) with Bowtie2 (Johns
Hopkins University, Maryland). Variant calling was performed with VarScan
(Washington University School of Medicine, Missouri) with a threshold for
the minimummutated allele percentage (MAP) of 1%. Variant calls in virtual
contact file (.vcf) format were then annotated through ANNOVAR (Univer-
sity of Pennsylvania). All results obtained by NGSwere confirmed by Sanger
sequencing.Mutagenesis, cell culture, and functional tests
Site-directed mutagenesis of the NLRP3wild-type (WT) expression vector
(pNLRP3-WT) was performed to generate the plasmids carrying the missense
variations identified in the patients: pNLRP3-Glu569Gly, pNLRP3-
Glu569Lys, and pNLRP3-Gly769Ser.
Human embryonic kidney HEK293T cells stably expressing green
fluorescent protein (GFP)-tagged-ASC and FLAG-tagged procaspase1 (desig-
nated ASC-GFP_C1-FLAG) were transfected with 375 ng of mentioned
plasmids using FUGENE HD (Promega, Madison, Wis). After 24 hours, the
transfected cells were observed using a Nikon Eclipse TS100 inverted
fluorescent microscope (Nikon Instruments, Melville, NY). Manual counting
of cells containing ASC-GFP specks was then performed in 5 randomly
selected fields at 203 magnification. The percentage of speck-positive cells
was calculated as the number of specks divided by the total number of counted
cells.
Human monocytic THP1 cells were initially primed with 100 ng/mL
phorbol 12-myristate 13-acetate for 3 hours, then transfected with 500 ng of
the plasmids using the FF-100 program in the 4D-Nucleofector, Amaxa
(Lonza Group, Basel, Switzerland). Transfected THP1 cells were treated
directly with 100 ng/mL LPS at 378C. After 24 hours, cytokine measurements
by ELISA assays were performed following manufacturer’s instructions
(R&D Systems, Minneapolis, Minn).
TABLE I. Clinical and molecular characteristics of 3 NLRP3-AID patients
Proband I Proband II Proband III
Phenotype MWS MWS CINCA
Age at onset Birth 3 months Birth
Fever-urticaria-arthralgia 1 1 1
Adenopathy 1 1 1
Hearing loss 1 1 –
Papilledema 1 – 1
Facial dysmorphia (frontal bossing) – - 1
Aseptic meningitidis – – 1
Other signs Clubbing fingers,
splenomegaly,
monoclonal IgGk
Nausea, diarrhea, clubbing fingers Mild growth retardation,
diarrhea, conjunctivitis,
developmental delay, autism
spectrum disorder, orchitis
NLRP3 variations (MAP) c.1705G>A,
p.(Glu569Lys) (7%)
c.1705G>A, p.(Glu569Lys) (13%) c.2305G>A, p.(Gly769Ser) (50%)
c.1706A>G p.(Glu569Gly) (10%)
TABLE II. NLRP3 DNA sequencing data in different cell types of the 3 NLRP3-AID patients
Proband I
MAP (mutated reads/to-
tal reads)
Proband II
MAP (mutated reads/to-
tal reads)
Proband III
MAP (mutated reads/to-
tal reads)
Mosaic mutation c.1705G>A
p.(Glu569Lys)
c.1705G>A
p.(Glu569Lys)
c.1706A>G
p.(Glu569Gly)
Peripheral blood 7 (70/951) 13 (75/581) 10 (15/148)
Monocytes 19 (200/1046) 15 (99/667) 9 (81/931)
Neutrophils 15 (165/1103) 14 (113/826) 9 (81/946)
B cells 17 (190/1110) 13 (104/773) 7 (52/758)
T cells 7 (96/1282) 11 (90/795) 10 (53/505)
Buccal cells 5 (69/1451) ND ND
ND, Not determined.
Values are percentages (n/n).
MAP is given by the ratio of the mutated reads divided by the total number of reads determined by NGS.
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mutations
Literature review ofNLRP3mutations was performed in PubMed using the
terms ‘‘NLRP3’’ and ‘‘mutation’’. Based on the classification of the American
College of Medical Genetics,14 only pathogenic and likely pathogenic muta-
tions were taken into account.NLRP3 crystal structure analysis
NLRP3 crystal structure analysis was performed using the human NLRP3
crystal (Protein Data Bank accession number 6NPY) by Sharif et al.3 The 3-
dimensional structure was visualized with the PyMOL software (Schr€odinger,
New York, NY).Statistical analyses
Differences were analyzed using the unpaired Student t test and were
plotted with the Prism 5 (GraphPad Software, San Diego, Calif). A P value
of less than .05 was considered statistically significant.RESULTS
Clinical phenotype of NLRP3-AID patients
We studied 3 unrelated patients presenting with early onset of
fever, urticaria, arthralgia, and inflammatory biological profile.
Probands I and II, both 50 years old, also developed sensorineural
hearing loss around the age of 30 and were, therefore, suggestiveof MWS. Proband III, a 4-year-old boy, displayed a clinical
phenotype evocative of CINCA shortly after birth (Table I, and
see Data E1 in this article’s Online Repository at www.
jacionline.org). None of the patients had a family history of AID.
To identify the molecular defect responsible for the patients’
phenotype, we followed an NGS approach based on the targeted
sequencing of the main genes so far involved in AIDs. For
probands I and II, no mutation was detected by a previous NLRP3
analysis by Sanger sequencing.
The c.1705G>A, p.(Glu569Lys) missense variation with a
MAP of 7% and 13% was identified in peripheral blood DNA of
probands I and II, respectively (Table II, and see Fig E1 in this ar-
ticle’s Online Repository at www.jacionline.org). This variation,
which is absent from the Genome Aggregation Database (gno-
mAD; Broad Institute, Cambridge, Mass), has already been re-
ported in several NLRP3-AID patients.11,12,15-18
In proband III, the NGS analysis revealed a novel heterozygous
NLRP3 variation, the c.2305G>A, p.(Gly769Ser), which is not
described in gnomAD and, according to the MaxEntScan soft-
ware (Massachusetts Institute of Technology, Cambridge,
Mass), is not predicted to affect splicing. In the 3-dimensional
structure of NLRP3, Gly769 is located on an external part of an
LRR motif (see Fig E2 in this article’s Online Repository at
www.jacionline.org), outside the region that interacts with
NEK7. Secondarily, the access to parents’ DNA samples revealed
that p.(Gly769Ser) was inherited from the asymptomatic father,
FIG 1. Impact of NLRP3 mutations on ASC-speck formation. HEK (ASC-
GFP_C1-FLAG) cells were transfected with 375 ng of the expression plas-
mids encoding the WT NLRP3 or the NLRP3 protein carrying the missense
variations p.(Glu569Gly), p.(Glu569Lys), and p.(Gly769Ser) or the EV. The
percentage of ASC specks was calculated as described in the methods. Re-
sults represent themeans1 SDs from 3 independent experiments. P values
were calculated using unpaired Student t test as compared to the WT.
**P < .01; ns 5 nonsignificant.
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NGS data were therefore subsequently reanalyzed using a
mosaic-specific pipeline and the c.1706A>G, p.(Glu569Gly) vari-
ation with a MAP of 9% in peripheral blood DNAwas detected.
This variation, absent from gnomAD, has never been reported
in NLRP3-AID patients.
The cellular distribution of the identified mosaic variations was
then determined by NGS and Sanger sequencing of DNA isolated
from cells of different embryonic origins. In proband I, who
carries the p.(Glu569Lys) variation, a wide cellular distribution of
the mutated allele was found with MAP ranging from 5% to 19%.
It ranged from 11% to 15% in proband II who also carries the
p.(Glu569Lys) variation. It is worth noting that proband III, who
had the most severe phenotype (CINCA) and carries the
p.(Glu569Gly) missense variation, displayed the lowest rate of
the mutated allele (ranging from 7% to 10%, depending on the
analyzed cell types) (Table II, and Fig E1).Functional consequences of identified NLRP3
variations
To assess the pathogenicity of the identified NLRP3 variations,
we studied ASC-speck formation, a common readout of inflamma-
some activation.19 In agreement with the known role of NLRP3 in
inflammasome assembly and ASC-speck formation, cells trans-
fected with pNLRP3-WT displayed a significantly higher percent-
age of ASC specks as compared to cells transfected with the empty
vector (EV) alone. However, no significant difference was
observed between the cells transfected with the constructs carrying
either the germline variant (pNLRP3-Gly769Ser) or the WT
sequence. In contrast, cells transfected with pNLRP3-Glu569Gly
or with pNLRP3-Glu569Lys (used as a positive control of inflam-
masome activation) showed a significantly higher percentage of
ASC specks as compared to cells transfected with pNLRP3-WT.
Therefore, a gain-of-function effect on inflammasome activationwas observed for p.(Glu569Gly), leading us to classify this varia-
tion as pathogenic (Fig 1).
To further assess the functional consequences of the
p.(Gly769Ser) variation, we tested its impact on cytokine
secretion. To this end, THP1 cells were transfected with the EV,
pNLRP3-WT, pNLRP3-Glu569Lys (used as positive control) or
pNLRP3-Gly769Ser and treated with LPS, a well-known acti-
vator of the NLRP3 inflammasome. IL1b secretion was measured
in the cell culture supernatants, and significantly higher levels
were found in the supernatant of cells transfected with pNLRP3-
Glu569Lys as compared to cells transfected either with pNLRP3-
WT or with the EV. When compared with WT-NLRP3, similar
amounts of secreted IL1b were measured for the p.(Gly769Ser)
variant (see Fig E3 in this article’s Online Repository at www.
jacionline.org). Taken together, these results led us to classify
the p.(Gly769Ser) variant as probably benign.Different NLRP3mutations occur in somatic mosaic
and germinal states
In an attempt to identify possible germline- and mosaic-
specific characteristics of NLRP3 mutations, we reinterpreted
all previously reported NLRP3 variations according to both the
associated disease severity and their localization in the protein do-
mains. The 3 unrelated NLRP3-AID patients with mutations
involving the same residue but associated with different pheno-
typic severity were included in this study. Based on the American
College of Medical Genetics classification of sequence varia-
tions,14 we classified as ‘‘likely pathogenic’’ or ‘‘pathogenic’’
90 distinct NLRP3 mutations identified in 277 patients: 33 so-
matic mosaic mutations in 54 unrelated patients and 65 germline
mutations reported in 223 unrelated patients (Fig 2, and see Table
E1 in this article’s Online Repository at www.jacionline.org). It is
worth noting that half of the reported cases (27 of 54) with mosaic
mutations carry mutations located in the HD2 domain of NLRP3,
including the p.(Gly569Lys) mutation, whereas only 9% of the
patients (20 of 223) with germline mutations carry mutations
located in this region (Fig 2). A second mosaic mutational hot
spot (10 of 54, 18.5%) involves Phe304 to Gly309 amino acids
that overlap the Walker B motif of the NBD. Among all reported
mutations, only 8 of them have been found in both a mosaic and a
germinal state (Fig 3). These 8 mutations were identified in a
germinal state in 16 patients (of 223, 7.2%), and it is noteworthy
that all these patients presented with the severe CINCA
phenotype. The same mutations were identified in mosaic
state in 22 patients (of 54, 40.7%) who displayed moderate
(MWS) to severe (CINCA) phenotypes (Fig 3). On the other
hand, the most frequent germline mutations, such as
p.(Thr350Met), p.(Arg262Trp), p.(Asp305Asn), p.(Leu355Pro),
and p.(Ala441Val), have never been reported in a mosaic state
(Fig 4, A), whereas some of these mutations involve amino
acids that are changed in other substitutions in mosaic
state—p.(Arg262Pro), p.(Asp305His), p.(Asp305Ala), and
p.(Ala441Pro) (Fig 2).
With the aim to further assess the functional impact of the
mutations, we located on the crystal structure of NLRP33 the 5
amino acids involved in the most frequently reported mutations
in mosaic and germinal states. Noteworthy, the mosaic mutations
are located in the core of the NACHT domain close to the ATPase
domain, while the germline mutations are scattered throughout
the NACHT domain (Fig 4, B).
FIG 2. Somatic mosaic and germlineNLRP3mutations on a domain organizationmodel of the protein. Top,
All mutations reported in a mosaic state. Bottom, All mutations reported in a germinal state. The 5 most
frequently reported mutated amino acids are in red. The asterisks denote mutations identified in this study.
The Walker A and Walker B motifs are in yellow and green, respectively. PYD, pyrin domain.
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For an optimal medical care of patients with NLRP3-AID, an
early molecular NLRP3 diagnosis is essential. Indeed, only 1 of
the 3 patients identified in the current study received an effective
anti-IL1 treatment prior to the identification of a NLRP3 muta-
tion. Although the use of NGS-based technologies increases the
sensitivity of detection of somatic mutations usually undetect-
able by Sanger sequencing, 2 critical points are to be followed
for an accurate molecular diagnosis of NLRP3-AIDs: (1) high-
depth sequencing and specific bioinformatics pipelines are
necessary to detect low level mosaicisms; (2) intrafamilial
segregation studies of germline variations and functional assays
of all newly identified variations are mandatory, because, as
shown here, a benign sequence variation can hide the pathogenic
one.
By studying the level of mosaicism of the identified mosaic
mutations in different cell types, we observed a wide distribu-
tion, indicating that the mutational event arose early during
embryogenesis. However, in proband I, a higher percentage of
the mutated allele was observed in myeloid cells and B
lymphocytes. A similar pattern was already observed in adult
patients with a late onset of the disease.11We did not observe any
correlation between the level of mosaicism and the severity of
the disease phenotype, neither among the 3 patients, nor in thepreviously reported ones (Fig 3), thereby suggesting that addi-
tional genetic and/or environmental factors might modulate
the expressivity of NLRP3-AIDs.
The amino acid Glu569 of NLRP3 is the most frequently
affected residue involved in mosaic mutations.7 The c.1705G>A
p.(Glu569Lys) mutation has been reported (including the current
study) in 10 patients.11,12,15-18 Of note, this G>A transition is
located on a cytosine-phosphate-guanine (CpG) dimer that favors
this type of mutational event.20 Two other mosaic mutations
—c.1705G>C p.(Glu569Gln)11 and c.1706A>G p.(Glu569Gly)
(proband III)— implicate the same amino acid without involving
a CpG dimer. Overall, Glu569 is affected in 22% of patients (12 of
54) carrying a mosaic mutation and in only 0.4% of patients (1 of
223) with a germline mutation. The patients carrying a mosaic
mutation involving Glu569 had either a moderate (n5 7) or a se-
vere phenotype (n5 5).11,12,15-18 It is worth noting that the single
patient with a germline mutation involving this residue had a very
severe neonatal CINCA syndrome,21 thereby suggesting that mu-
tations found only in mosaic state could be incompatible with life
if present in germinal state.
While taking into account all reported NLRP3 mutations
(n 5 90) identified in 277 patients, further observations can be
made. First, we noticed that in half of the patients with a mosaic
mutation (27 of 54), the affected amino acid lies on a short segment
FIG 3. Characteristics of the NLRP3 mutations reported in both mosaic and germline states. Left, Venn di-
agram of mosaic and somatic NLRP3mutations is presented. Right, The 8 common mutations carried by 38
patients in either a mosaic or a germinal state and the phenotypes of the corresponding patients are
detailed. For the p.(Glu569Lys) mutation (E569K), the levels of mosaicism are also given.
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whereas only 9% of the patients (20 of 223) with a germline mu-
tation carry a mutation in that region. In an attempt to explain this
striking observation, we highlighted the mutated amino acids on
the crystal structure of NLRP3. The region spanning Tyr565 to
Tyr572 is located in the core of the NACHT domain facing the
Walker Bmotif, a sequence involved in ATP hydrolysis and essen-
tial for NLRP3-inflammasome activation.22 Interestingly, the re-
gion of the Walker B motif includes the second hot spot (Phe304
to Gly309) for mosaic mutations (18.5%, 10 of 54 patients). The
2 mutational hot spots account for 68.5% of the patients (37 of
54) with mosaic mutations, but only 26.9% of the patients (60 of
223) with germline mutations. Second, only a minority of the re-
ported NLRP3mutations (8 of 90) were identified in both somatic
mosaic and germinal states. In germinal state, these 8 mutations
concern 16 unrelated patients (of 223, 7.1%) who are all sporadic
cases presenting with the severe CINCA phenotype.5,21-28 Third,the most frequent germline mutations have never been reported
in NLRP3-AID patients in a mosaic state despite their location
on CpG dimers for 4 of them (Figs 2 and 4, A). It is tempting to
speculate that those mutations reported in a germinal state only
may display a very mild phenotype (or even be asymptomatic) if
present in a mosaic state and could, therefore, escape diagnosis.
In keeping with this hypothesis, the single report of the
p.(Thr350Met) mutation in a mosaic state concerns an asymptom-
atic mother who transmitted the mutation to her child who pre-
sented with an MWS phenotype.29 Conversely, somatic mosaic
mutations could be responsible for severe phenotypes or be incom-
patible with life if present in a germinal state.18 A negative selec-
tion of gametes carrying the most activating mutations is another
attractive hypothesis. Indeed, recent studies have shown a promi-
nent NLRP3 staining of peritubular cells of testis from patients
with impaired spermatogenesis.30,31 Moreover, 2 different studies
suggested hypofertility in NLRP3-AID patients.32,33
FIG 4. Patients’ phenotypes and localization in the 3-dimensional structure of NLRP3 of the most frequently
reportedmutations.A, Characteristics associatedwith themost frequentmosaic and germlinemutations. B,
The 5 most frequently mutated amino acids in mosaic state (in red), in germline state (in blue), and in both
mosaic and germinal states (in green) are highlighted. Cyan, adenosine diphosphate; yellow, Walker
A motif; green, Walker B motif.
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underline that the phenotypes observed in NLRP3-AID patients
(from FCAS to CINCA) represent only a part of the phenotypic
spectrum associated with a mutation in NLRP3. Indeed, on the
basis of the epidemiological data presented in this study, it ap-
pears that the NLRP3 mutations cover a phenotypic spectrum
larger than that revealed by the patients’ phenotype: some
mutations could be lethal or asymptomatic (and therefore not
reported) depending on their molecular characteristics (ie,
germinal/mosaic status, localization in the protein, and amino
acid change).
In conclusion, as illustrated here, the early detection of an
NLRP3mosaicism is of key importance to establish the diagnosis
of NLRP3-AID and to initiate anti-IL1 treatment. Our study also
sheds light on a diagnostic pitfall due to the identification of
several NLRP3 sequence variations in the same patient, thereby
underlining the importance of functional and segregation studies
to assess the pathogenicity of the identified sequence variations.
The 2 hot spots for mosaic mutations are located around the
Walker B motif, essential for NLRP3-inflammasome activation.
The phenotypic spectrum of NLRP3-AIDs appears to be related
to the germinal/mosaic status and localization of the underlying
mutations.We are grateful to the patients and the parents whose cooperation made this
study possible.
Key messages
d This study, which reviews and reinterprets all previously
reported NLRP3 variations, shows on the human NLRP3
cryoelectron microscopy structure that the mosaic
mutations are mainly situated in the core of the
NLRP3-inflammasome activating domain, while germline
mutations are scattered throughout this domain.
d Only a minority of NLRP3 mutations is found in both
germinal and somatic mosaic states. It is noteworthy
that in the germinal state, those mutations were all found
in sporadic cases presenting with the most severe AID
phenotype. The mutation localization in the NLRP3 pro-
tein but also the amino acid change could account for the
occurrence of mutations in mosaic or germinal states.
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